APA (7th ed.) Citation

Bazarbachi, A., & Dreger, P. (2018). Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 125(1), . https://doi.org/10.1002/cncr.31755

Chicago Style (17th ed.) Citation

Bazarbachi, Ali, and Peter Dreger. "Brentuximab Vedotin for Recurrent Hodgkin Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the EBMT Lymphoma Working Party." Cancer 125, no. 1 (2018). https://doi.org/10.1002/cncr.31755.

MLA (9th ed.) Citation

Bazarbachi, Ali, and Peter Dreger. "Brentuximab Vedotin for Recurrent Hodgkin Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the EBMT Lymphoma Working Party." Cancer, vol. 125, no. 1, 2018, https://doi.org/10.1002/cncr.31755.